Clarus Therapeutics (CRXT) Misses Q1 EPS by 21c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/27/2026

1. ORCL
2. AVGO
3. CDNS
4. ANT
5. META
6. BA
7. SPY
8. INTC
9. JBLU
10. HOOD

Go back to Clarus Therapeutics (CRXT) Misses Q1 EPS by 21c

Clarus Therapeutics Reports First Quarter 2022 Financial and Operating Results

May 16, 2022 4:05 PM EDT

First quarter 2022 net revenue increased 72% year-over-year to $4.0 million

First quarter 2022 total prescription growth for JATENZO® increased 12% sequentially and increased 75% year-over-year

Conference call and webcast today at 5:15 p.m. ET

NORTHBROOK, Ill., May 16, 2022 (GLOBE NEWSWIRE) -- Clarus Therapeutics Holdings, Inc. (Clarus) (Nasdaq: CRXT), a pharmaceutical company dedicated to providing solutions to unmet medical needs by advancing androgen and metabolic therapies for men and women, today reported financial results for the first quarter of 2022.

We delivered a strong first quarter, as the... More